Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial.

ABSTRACT:

Background

Vaping cessation is virtually unexplored. The efficacy and safety of varenicline for vaping cessation has not been studied and rigorous research is required to advance best practice and outcomes for people who use electronic cigarettes (EC) and want to quit. The objective is to evaluate the efficacy and safety of varenicline (1 mg BID, administered for 12 weeks, with follow-up to week 24) combined with vaping cessation counseling in exclusive daily EC users intending to quit vaping.

Methods

Design: Double-blind, randomized, parallel-group, placebo-controlled trial.

Setting

The study took place at a University-run smoking cessation center.

Participants

People who exclusively use ECs daily and intend to quit vaping.

Intervention

A total of 140 s

SUBMITTER: Caponnetto P 

PROVIDER: S-EPMC10321010 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature